In this view, plasma GFAP could serve as a valid surrogate blood biomarker for the identification of AD co-pathology in ALS patients, given the suboptimal value of plasma p-tau181 in these subjects due to its likely peripheral source, as already demonstrated in two studies [22,25] and confirmed in this work in a larger cohort. This evidence concerns the gene GFAP and Alzheimer disease.